Drug Therapy for Nasopharyngeal Carcinoma: Cytotoxic and Targeted Therapy

2010 ◽  
pp. 149-160
Author(s):  
Brigette B. Y. Ma ◽  
Anthony T. C. Chan
Keyword(s):  
Targeted Therapy ◽  
Drug Therapy ◽  
Nasopharyngeal Carcinoma

Epstein–Barr virus-targeted therapy in nasopharyngeal carcinoma

2015 ◽  
Vol 141 (10) ◽  
pp. 1845-1857 ◽  
Author(s):  
Sharon D. Stoker ◽  
Zlata Novalić ◽  
Maarten A. Wildeman ◽  
Alwin D. R. Huitema ◽  
Sandra A. W. M. Verkuijlen ◽  
...  
Keyword(s):  
Targeted Therapy ◽  
Nasopharyngeal Carcinoma ◽  
Epstein Barr Virus ◽  
Barr Virus ◽  
Epstein Barr

scholarly journals Advances in targeted therapy mainly based on signal pathways for nasopharyngeal carcinoma

2020 ◽  
Vol 5 (1) ◽  
Author(s):  
Yuanbo Kang ◽  
Weihan He ◽  
Caiping Ren ◽  
Jincheng Qiao ◽  
Qiuyong Guo ◽  
...  
Keyword(s):  
Targeted Therapy ◽  
Nasopharyngeal Carcinoma ◽  
Southern China ◽  
Intensity Modulated Radiotherapy ◽  
Neck Region ◽  
Epidemiological Data ◽  
Living Standard ◽  
Signal Pathways ◽  
Endemic Region ◽  
Incidence And Mortality

AbstractNasopharyngeal carcinoma (NPC) is a malignant epithelial carcinoma of the head and neck region which mainly distributes in southern China and Southeast Asia and has a crucial association with the Epstein–Barr virus. Based on epidemiological data, both incidence and mortality of NPC have significantly declined in recent decades grounded on the improvement of living standard and medical level in an endemic region, in particular, with the clinical use of individualized chemotherapy and intensity-modulated radiotherapy (IMRT) which profoundly contributes to the cure rate of NPC patients. To tackle the challenges including local recurrence and distant metastasis in the current NPC treatment, we discussed the implication of using targeted therapy against critical molecules in various signal pathways, and how they synergize with chemoradiotherapy in the NPC treatment. Combination treatment including targeted therapy and IMRT or concurrent chemoradiotherapy is presumably to be future options, which may reduce radiation or chemotherapy toxicities and open new avenues for the improvement of the expected functional outcome for patients with advanced NPC.

scholarly journals The pharmacoeconomic efficacy of chemotherapy for malignant neoplasms of the bronchus and lung

2020 ◽  
Vol 13 (1) ◽  
pp. 13-22
Author(s):  
S. K. Yarovoy ◽  
I. B. Shikina
Keyword(s):  
Lung Cancer ◽  
Targeted Therapy ◽  
Drug Therapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Malignant Neoplasm ◽  
Small Cell ◽  
Malignant Neoplasms ◽  
Small Cell Lung ◽  
The Cost

Aim: to conduct a pharmacoeconomic analysis of chemotherapy taking into account the types of malignant neoplasms of the bronchi and lung, and to calculate pharmacoeconomic efficiency.Materials and methods. The materials for the study were the data of the Moscow Cancer Hospital n.a. D.D. Pletnev for 2019. The cost of drugs was calculated according to the data of the website aptekamos.ru (for June 2019).Results and discussion. For 300 patients with squamous non-small cell lung cancer, it is required 3205.5 courses of chemotherapy of I (1747.5) and II (1458) lines. For 200 patients with non-small cell non-squamous EGFR positive lung cancer, it is required 1,413.1 courses of chemotherapy and targeted therapy. For 70 patients with non-squamous cell non-small cell lung cancer with ALK mutation, it is required 450.2 courses of chemotherapy and targeted therapy. For 280 patients with non-squamous cell non-small cell lung cancer lung cancer without mutations, it is required 7515 chemotherapy courses. For 150 patients with small cell lung cancer, it is required 1,656.8 courses of chemotherapy. Thus, a total sample of 1000 patients, excluding the type of malignant neoplasm of broncus and lung are required 14,239.8 chemotherapy courses. The determined cost of 67,000 rubles for the average chemotherapy course per patient takes into account the necessary colony stimulating factors, antiemetic, infusion solutions, etc.; in the case of treatment with erlotinib (the length of the course is 8 months), the cost is 663,408.0 rubles; in the case of treatment with crizotinib (the length of the course is 11 months course), the cost is 2044110.0 rubles. The average cost of drug therapy for one patient with malignant neoplasm of bronchus and lung is 1136155.9 rubles.Conclusion. We determined the pharmacoeconomic dependence of a chemotherapy on the type of malignant neoplasms of bronchus and lung and the main anticancer drug used. The median of the overall survival rate of patients with malignant neoplasms of bronchus and lung was 42 months. The average cost of drug therapy was 27051.3 rubles per month. The median survival rate without therapy is 3 months. Thus, therapy can extend the patient’s life by an average of 39 months. The cost of a month of a saved life is 29132.2 rubles. 

Abstract 2190: Repurposing the FDA-approved antiviral drug ribavirin as targeted therapy for nasopharyngeal carcinoma

2019 ◽  
Author(s):  
Andy S. Ding ◽  
Joshua Casaos ◽  
Sakibul Huq ◽  
Henry Brem ◽  
Nicolas Skuli ◽  
...  
Keyword(s):  
Targeted Therapy ◽  
Nasopharyngeal Carcinoma ◽  
Antiviral Drug

Abstract B06: Repositioning the FDA-approved antiviral drug ribavirin as targeted therapy for nasopharyngeal carcinoma

2020 ◽  
Author(s):  
Sakibul Huq ◽  
Joshua Casaos ◽  
Michael Peters ◽  
Yuanxuan Xia ◽  
Andy Ding ◽  
...  
Keyword(s):  
Targeted Therapy ◽  
Nasopharyngeal Carcinoma ◽  
Antiviral Drug

scholarly journals Novel EBV LMP-2-affibody and affitoxin in molecular imaging and targeted therapy of nasopharyngeal carcinoma

2020 ◽  
Vol 16 (1) ◽  
pp. e1008223 ◽  
Author(s):  
Shanli Zhu ◽  
Jun Chen ◽  
Yirong Xiong ◽  
Saidu Kamara ◽  
Meiping Gu ◽  
...  
Keyword(s):  
Targeted Therapy ◽  
Molecular Imaging ◽  
Nasopharyngeal Carcinoma

scholarly journals Current Trends and Future Prospects of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma

2020 ◽  
Vol 22 (1) ◽  
pp. 240
Author(s):  
Naoya Kitamura ◽  
Shinya Sento ◽  
Yasumasa Yoshizawa ◽  
Eri Sasabe ◽  
Yasusei Kudo ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Targeted Therapy ◽  
Drug Therapy ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Molecular Targeted Therapy ◽  
Future Prospects ◽  
Current Trends ◽  
Anti Cancer

In recent years, advances in drug therapy for head and neck squamous cell carcinoma (HNSCC) have progressed rapidly. In addition to cytotoxic anti-cancer agents such as platinum-based drug (cisplatin and carboplatin) and taxane-based drugs (docetaxel and paclitaxel), epidermal growth factor receptor-tyrosine kinase inhibitors (cetuximab) and immune checkpoint inhibitors such as anti-programmed cell death-1 (PD-1) antibodies (nivolumab and pembrolizumab) have come to be used. The importance of anti-cancer drug therapy is increasing year by year. Therefore, we summarize clinical trials of molecular targeted therapy and biomarkers in HNSCC from previous studies. Here we show the current trends and future prospects of molecular targeted therapy in HNSCC.

scholarly journals The role of targeted therapy in the management of patients with AML

2017 ◽  
Vol 1 (24) ◽  
pp. 2281-2294 ◽  
Author(s):  
Alexander E. Perl
Keyword(s):  
Acute Myeloid Leukemia ◽  
Targeted Therapy ◽  
Drug Therapy ◽  
Myeloid Leukemia ◽  
Standard Of Care ◽  
Gemtuzumab Ozogamicin ◽  
Targeted Agents ◽  
The Us ◽  
Acute Myeloid

Abstract Drug therapy for acute myeloid leukemia (AML) is finally undergoing major changes in 2017. This is due to the US Food and Drug Administration’s approval of several new, targeted agents (midostaurin, enasidenib, and gemtuzumab ozogamicin). Paired with the recent approval of a novel liposomal formulation of daunorubicin/cytarabine (CPX-351/Vyxeos), the standard of care is changing rapidly in AML for subgroups. This review will focus on currently approved agents and promising novel agents in development and will highlight controversial areas in targeted treatment.

Sign in / Sign up

Export Citation Format

Share Document